澳大利亚癫痫的经济成本:基于生产力的分析
该研究采用生命表模型,对2017年15-69岁澳大利亚工作年龄癫痫患者随访至70岁,估算超额死亡、寿命损失和生产力调整生命年损失。
核心结论
- 癫痫对澳大利亚工作年龄人群造成显著的社会和经济负担。
- 相对温和的癫痫控制改善即可带来可观的经济效益。
研究设计与样本
- 采用生命表模型,对2017年15-69岁澳大利亚工作年龄癫痫患者随访至70岁。
- 使用2017年已发表的人群和癫痫相关数据(患病率、死亡率、生产力)。
- 通过重新模拟假设队列无癫痫,将结局差异归因于癫痫。
- 模拟无发作患者比例从基线70%提高至75%和80%的情景。
主要发现
- 预测工作年龄癫痫患者至70岁经历超过14,000例超额死亡。
- 预测超过78,000年寿命损失年和超过146,000生产力调整生命年损失。
关键数值与推荐
- 基线无发作患者比例为70%。
临床怎么用
- 临床应重视改善癫痫发作控制,以降低死亡和生产力损失。
- 无发作率的小幅提升可能带来显著的社会经济效益。
局限性
- 基于模型预测和已发表数据,非直接队列观察。
- 结果依赖于2017年数据及模型假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the health economic burden of epilepsy for Australians of working age by using life table modeling and to model whether improved seizure control may result in substantial health economic benefits. METHODS: Life table modeling was used for working age Australians aged 15-69 years with epilepsy and the cohort was followed until age 70 years. Published 2017 population and epilepsy-related data regarding epilepsy prevalence, mortality, and productivity were used. This model was then re-simulated, assuming the cohort no longer had epilepsy. Differences in outcomes between these cohorts were attributed to epilepsy. Scenarios were also simulated in which the proportion of seizure-free patients increased from baseline 70% up to 75% and 80%. RESULTS: In 2017, Australians of working age with epilepsy followed until age 70 years were predicted to experience over 14,000 excess deaths, more than 78,000 years of life lost, and over 146,000 productivity-adjusted life years lost due to epilepsy. This resulted in lost gross domestic product (GDP) of US $22.1 billion. Increasing seizure freedom by 5% and 10% would reduce health care costs, save years of life, and translate to US $2.6 billion and US $5.3 billion GDP retained for seizure freedom rates of 75% and 80%, respectively. CONCLUSIONS: Our study highlights the considerable societal and economic burden of epilepsy. Relatively modest improvements in overall seizure control could bring substantial economic benefits.
引用
- Foster E, Chen Z, Zomer E, et al. The costs of epilepsy in Australia: A productivity-based analysis. Neurology. 2020. PMID: 32934163. doi:10.1212/WNL.0000000000010862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。